Skip to main content Skip to main content

chronic skin conditions

A white and beige background with a black and white design

Could This New HS Injection Mean Fewer Flares?

By Originally Published on Dermatology TimesNovember 12, 2026

In a large phase 3 trial, fewer people on the experimental drug lutikizumab had flares, and skin pain improved as early as week one. It isn’t approved yet.

Omlyclo, a New Biosimilar for Chronic Hives, Is Now Available

Omlyclo, a New Biosimilar for Chronic Hives, Is Now Available

By Originally Published on Dermatology TimesOctober 30, 2026
Dupixent May Ease More Than Just the Itch of Chronic Hives

Dupixent May Ease More Than Just the Itch of Chronic Hives

By Originally Published on HCPLiveOctober 30, 2026
Teens With Hidradenitis Suppurativa Now Have a New Treatment Option

Teens With Hidradenitis Suppurativa Now Have a New Treatment Option

By Originally Published on Dermatology TimesSeptember 14, 2026

For teens 12 and older with HS, this approval adds a biologic with a different mechanism to the treatment mix.

A Once-Monthly Injection Shows Lasting Results for This Painful Skin Condition

A Once-Monthly Injection Shows Lasting Results for This Painful Skin Condition

By Amaya GarciaSeptember 10, 2026

A year of data shows the improvements just kept building.